Regarding the existing anti-TNF therapy (adalimumab versus infliximab), no significant differences were observed among IBD patients without prior COVID-19 infection in terms of anti-S-IgG (p = 1.0) and sVNT levels (p = 0.810) (refer to Supplemental Figure S1). Here, TNF is linked to inflammatory bowel disease.